AVEO Pharmaceuticals Inc
Prices are adjusted according to historical splits.
- Today's Low:
- Today's High:
- Open Price:
- 52W Low:
- 52W High:
- Prev. Close:
- Market Cap.:
- $521.45 million
- Book Value:
- Revenue TTM:
- $94.32 million
- Operating Margin TTM:
- Gross Profit TTM:
- $11.26 million
- Profit Margin:
- Return on Assets TTM:
- Return on Equity TTM:
AVEO Pharmaceuticals Inc had its IPO on 2010-03-12 under the ticker symbol AVEO.
The company operates in the sector and industry. AVEO Pharmaceuticals Inc has a staff strength of 114 employees.
Shares of AVEO Pharmaceuticals Inc opened at $15 at the start of the last trading session i.e. 2023-03-22.
The stocks traded within a range of $15 - $15, and closed at $15.
This is a 0% increase from the previous day's closing price.
A total volume of 0 shares were traded at the close of the day’s session.
In the last one week, shares of AVEO Pharmaceuticals Inc have increased by +0.4%.
AVEO Pharmaceuticals Inc's Key Ratios
AVEO Pharmaceuticals Inc has a market cap of $521.45 million, indicating a price to book ratio of 17.957 and a price to sales ratio of 5.4917.
In the last 12-months AVEO Pharmaceuticals Inc’s revenue was $94.32 million with a gross profit of $11.26 million and an EBITDA of $-24426000. The EBITDA ratio measures AVEO Pharmaceuticals Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, AVEO Pharmaceuticals Inc’s operating margin was -25.97% while its return on assets stood at -14.56% with a return of equity of -72.53%.
In Q3, AVEO Pharmaceuticals Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 100.7%.
AVEO Pharmaceuticals Inc’s PE and PEG Ratio
- Forward PE
- Trailing PE
Its diluted EPS in the last 12-months stands at $-1.203 per share while it has a forward price to earnings multiple of 48.0769 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into AVEO Pharmaceuticals Inc’s profitability.
AVEO Pharmaceuticals Inc stock is trading at a EV to sales ratio of 5.0812 and a EV to EBITDA ratio of -19.6673. Its price to sales ratio in the trailing 12-months stood at 5.4917.
AVEO Pharmaceuticals Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $101.23 million
- Total Liabilities
- $42.42 million
- Operating Cash Flow
- $7.00 million
- Capital Expenditure
- Dividend Payout Ratio
AVEO Pharmaceuticals Inc ended 2023 with $101.23 million in total assets and $0 in total liabilities. Its intangible assets were valued at $101.23 million while shareholder equity stood at $28.85 million.
AVEO Pharmaceuticals Inc ended 2023 with $0 in deferred long-term liabilities, $42.42 million in other current liabilities, 35000.00 in common stock, $-696331000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $77.40 million and cash and short-term investments were $77.40 million. The company’s total short-term debt was $11,495,000 while long-term debt stood at $38.68 million.
AVEO Pharmaceuticals Inc’s total current assets stands at $100.73 million while long-term investments were $0 and short-term investments were $0.00. Its net receivables were $19.76 million compared to accounts payable of $5.04 million and inventory worth $1.11 million.
In 2023, AVEO Pharmaceuticals Inc's operating cash flow was $7.00 million while its capital expenditure stood at $0.
Comparatively, AVEO Pharmaceuticals Inc paid $0 in dividends in 2023.
Other key metrics
- Current Trading Price
- 52-Week High
- 52-Week Low
- Analyst Target Price
AVEO Pharmaceuticals Inc stock is currently trading at $15 per share. It touched a 52-week high of $15 and a 52-week low of $15. Analysts tracking the stock have a 12-month average target price of $15.
Its 50-day moving average was $14.9 and 200-day moving average was $9.24 The short ratio stood at 2 indicating a short percent outstanding of 0%.
Around 19.3% of the company’s stock are held by insiders while 3446.5% are held by institutions.
Frequently Asked Questions About AVEO Pharmaceuticals Inc
AVEO Pharmaceuticals, Inc., an oncology-focused biopharmaceutical company, focuses on developing and commercializing medicines for patients with cancer. It markets FOTIVDA, an oral, next-generation vascular endothelial growth factor receptor tyrosine kinase inhibitor, which is used for the treatment of adult patients with relapsed or refractory advanced renal cell carcinoma (RCC). The company is also developing tivozanib for the treatment of RCC, hepatocellular carcinoma, ovarian cancer, immunologically cold tumors, and cholangiocarcinoma. In addition, it is developing Ficlatuzumab, a potent humanized immunoglobulin G1 (IgG1) monoclonal antibody that targets hepatocyte growth factor that is in a Phase II clinical trial for the treatment of head and neck squamous cell carcinoma, pancreatic cancer, and acute myeloid leukemia; AV-380, a potent humanized IgG1 inhibitory monoclonal antibody for the treatment or prevention of cachexia; AV-203, a potent humanized IgG1 monoclonal antibody that targets ErbB3; and AV-353 that targets the Notch 3 pathway. The company has collaborations and license agreements with AstraZeneca PLC; EUSA Pharma (UK) Limited; Biodesix, Inc.; CANbridge Life Sciences, Ltd.; Biogen Idec International GmbH; St. Vincent’s Hospital Sydney Limited; and Kyowa Kirin Co., Ltd. The company was formerly known as GenPath Pharmaceuticals, Inc. and changed its name to AVEO Pharmaceuticals, Inc. in March 2005. AVEO Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Boston, Massachusetts.